Sanjivani Paranteral Limited

Equities

SANJIVIN

INE860D01013

Pharmaceuticals

Market Closed - Bombay S.E. 06:14:33 2024-04-23 am EDT 5-day change 1st Jan Change
197.1 INR +1.70% Intraday chart for Sanjivani Paranteral Limited +34.13% +9.44%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sanjivani Parenterals CFO Steps Down MT
Sanjivani Paranteral Limited Announces Board Changes CI
Sanjivani Paranteral Limited Announces CFO Change CI
Sanjivani Paranteral Forms New Unit MT
Sanjivani Paranteral Limited Appoints Pooja Vijay Gohil as Company Secretary and Compliance Officer CI
Sanjivani Paranteral Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Sanjivani Paranteral Limited announced that it has received INR 248.0466 million in funding from Nabs Vriddhii LLP, Plasma Commercials Pvt. Ltd., Venus Orchards Pvt. Ltd., Ashika Global Securities Private Limited CI
Sanjivani Paranteral Limited announced that it expects to receive INR 248.0346 million in funding from Nabs Vriddhii LLP, Plasma Commercials Pvt.Ltd., Venus Orchards Pvt. Ltd, Ashika Global Securities Private Limited and other investors CI
Sanjivani Paranteral Limited Announces Resignation of Ritu Puglia from the Position of the Company Secretary CI
Sanjivani Paranteral Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Sanjivani Paranteral Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Sanjivani Paranteral Ties Up with Czech Republic-based Alevia Healthcare to Expand Business in EU MT
Sanjivani Paranteral Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023 CI
Sanjivani Paranteral Limited Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Sanjivani Paranteral Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Sanjivani Paranteral Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Sanjivani Paranteral Limited Appoints Monika Amit Singhania as Independent Director CI
Sanjivani Paranteral Limited Reports Earnings Results for the First Quarter Ended June 30, 2022 CI
Sanjivani Paranteral Limited Announces Appointment of Ritu Puglia as Company Secretary CI
Sanjivani Paranteral Limited Reports Earnings Results for the Full Year Ended March 31, 2022 CI
Sanjivani Paranteral Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022 CI
Sanjivani Paranteral Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021 CI
Sanjivani Paranteral Pays $1.2 Million Debt MT
Ashwani Khemka, Managing Director of Sanjivani Paranteral Limited completed the acquisition of additional 26% minority stake in Sanjivani Paranteral Limited (BSE : 531569). CI
Sanjivani Paranteral Limited. announced that it has received INR 15 million in funding from Next Orbit Ventures Private Limited CI
Chart Sanjivani Paranteral Limited
More charts
Sanjivani Paranteral Limited is engaged in the business of manufacturing pharmaceutical products. Its product category includes antibiotic, anti-emetic, non-steroidal anti-inflammatory drugs (NSAID) and analgesic, antimalarial, calcium and vitamin, sedative, steroid, cardiovascular, anti-fibrinolytic, anti-coagulant, vasoconstrictor, inotropic agent, anti-spasmodic, multivitamin, nutrition, iron, NSAID and analgesic, analgesic anti spasmodic, analgesic, and NSAID. Its antibiotic includes Netilmicin Sulphate, Amikacin Sulphate, and Gentamycin Sulphate. Its anti-emetic includes Ranitidine Hydrochloride, Metoclopramide, Ondansetron, and Promethazine. Its NSAID and analgesic includes Acetaminophen Injection and Diclofenac Sodium Injection. Its calcium and vitamin include Methylcobalamin 500 mcg/ml and Nicotinic Acid 10 mg/ml. Its sedative includes Midazolam Hydrochloride, Diazepam, and Dobutamine Hydrochloride. Its Iron includes iron Sucrose. Its analgesic includes Metamizole.
More about the company